NCBiotech News

We work hard to bring you news about North Carolina’s wide-ranging life sciences community. Please feel free to share it with others. And let us know if you have something we should know about.

RTI International -- a leading non-profit research institute in Research Triangle Park -- and Austin, Texas-based biotechnology company Asuragen have entered into a collaboration to look for a genetic disorder in North Carolina’s newborns.
Renaissance Computing Institute (RENCI) may be the most successful organization in North Carolina that few people have ever heard of. But that’s about to change.
TransEnterix, a medical device company located in Research Triangle Park, has received clearance from the U.S. Food and Drug Administration to market its Senhance Ultrasonic System.
Pairwise, a growing agriculture and food company that recently signed a lease for its new site in Durham’s Golden Belt complex downtown, expects to increase its 50 employee headcount by an additional 30 to 40 in 2019.
Fifteen STEM students at Immaculata Catholic Middle School in Durham partner with researchers at Precision BioSciences to send a genome editing experiment for the U.S. Naval Laboratory to the International Space Station, to explore whether the technology can help humans, plants and animals adapt to life outside Earth’s atmosphere.
GreenLight Biosciences Inc., which is developing RNA-based solutions for agriculture and pharmaceutical applications, has disclosed a $50 million first closing of its latest funding round.
The North Carolina Biotechnology Center has received two grants totaling nearly $200,000 from the N.C. Department of Agriculture and Consumer Services to validate production of purple carrots and ways to improve hemp crops.
Vast Therapeutics is celebrating the new year with Series A funding in excess of $15 million from Shionogi & Co., Ltd. (TYO: 4507) of Japan and a $300,000 award from the Cystic Fibrosis Foundation.
bluebird bio, a gene therapy company with operations in Durham, has entered into an exclusive license agreement with Inhibrx of La Jolla, Calif., to research, develop and commercialize cancer immunotherapies.
Aerie Pharmaceuticals, an ophthalmic pharmaceutical company based in Durham, has reported positive results from a pilot Phase 2 study of an eye drop intended to reduce high intraocular pressure (IOP), a cause of glaucoma.
Traditional seed breeding methods are slow and expensive. But technology can speed up the process of breeding hardier plants at lower cost, according to Hi Fidelity Genetics, a Durham-based crop breeding company using artificial intelligence to improve seed genetics that recently closed an $8.5 million Series A round of financing.
A potential drug for helping cancer patients withstand the side effects of chemotherapy showed positive results in a recent Phase 2 clinical trial involving small cell lung cancer, according to its developer, G1 Therapeutics of Research Triangle Park.
The three-cornered Research Triangle is also among America’s top-three places to start a business. That’s the conclusion of the newly published winter 2018 edition of Inc. magazine, on newsstands now.
Criticality, a budding hemp processing company in the small northeastern North Carolina farming town of Hobgood, in Halifax County, is converting a tobacco-buying facility in Wilson to bring the techniques of Good Manufacturing Practice to the state’s newly expanding CBD industry, to minimize or eliminate instances of contamination, mix-ups, and errors.
RedHill Biopharma, an Israeli company with U.S. headquarters and commercial operations in Raleigh, has closed on a $20 million public offering to fund the commercial launch of its gastrointestinal drug, Talicia. That will mean new jobs in the Raleigh area.
scroll back to top of page